The effect of tenidap on the anti-hypertensive efficacy of thiazide diuretics in patients treated for mild to moderate hypertension.
1. This randomised, placebo-controlled, double-blind, parallel-group study was conducted to assess the effect of tenidap sodium 120 mg, a novel anti-arthritic cytokine modulating drug, on the hypotensive efficacy of the thiazide diuretics hydrochlorothiazide or bendrofluazide. 2. Twenty-three male and female patients, aged 41-78 years, with mild to moderate, uncomplicated, essential hypertension controlled with thiazide diuretic therapy, received either a single daily dose of tenidap sodium 120 mg or matched placebo for 22 days in addition to their diuretic therapy. Changes between baseline and endpoint in supine and standing systolic and diastolic pressures and pulse rate were compared between treatment groups. 3. Daily treatment with tenidap reduced the anti-hypertensive efficacy of the thiazide diuretics. Blood pressure tended to increase marginally and the increase in mean standing diastolic pressure observed with tenidap was significantly greater than the change in the placebo group. All pressures tended to decrease in the placebo group and all endpoint measurements were within 7 mm Hg of baseline in both groups. 4. Treatment-related side effects of mild to moderate severity were reported in two subjects receiving tenidap, but in neither case was treatment discontinued. Two subjects receiving placebo also experienced side effects considered to be treatment-related and both were withdrawn from the study. 5. The results of this study suggest that tenidap may be given to patients treated for mild to moderate essential hypertension controlled with thiazide therapy; however, the patient's blood pressure should be regularly monitored.
Rapeport
W G
WG
Early Clinical Research Group, Pfizer Central Research, Sandwich, Kent, UK.
Grimwood
V C
VC
Korlipara
K
K
Grillage
M G
MG
James
I
I
Anderton
J L
JL
Selfridge
D I
DI
D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D001539:Bendroflumethiazide / Q000494:pharmacology / Q000627:therapeutic use; D004232:Diuretics; D004311:Double-Blind Method; D004347:Drug Interactions; D005260:Female; D006801:Humans; D006852:Hydrochlorothiazide / Q000494:pharmacology / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy*; D007211:Indoles / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D000078183:Oxindoles; D049993:Sodium Chloride Symporter Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D013997:Time Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D004232:Diuretics; D007211:Indoles; D000078183:Oxindoles; D049993:Sodium Chloride Symporter Inhibitors; D006852:Hydrochlorothiazide; D001539:Bendroflumethiazide; C062866:tenidap